Why Armata Pharmaceuticals, Inc.’s (ARMP) Stock Is Down 7.62%
As of Wednesday, September 23, Armata Pharmaceuticals, Inc.’s ARMP share price has dipped by 7.62%, which has investors questioning if this is right time to buy.Jenna Brashear
Stock Evaluator: Armata Pharmaceuticals, Inc. (ARMP)
Armata Pharmaceuticals, Inc. ARMP
$3.70
-0.50
-11.90%
September 23, 2026 12:42:27 PM
EST
Volume: 210,660
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
AMEX | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
Commentary & Analysis
Why Armata Pharmaceuticals, Inc.’s (ARMP) Stock Is Down 11.67%
As of Wednesday, September 23, Armata Pharmaceuticals, Inc.’s ARMP share price has dipped by 11.67%, which has investors questioning if this is right time to buy.Omar Beirat
Why Armata Pharmaceuticals, Inc.’s (ARMP) Stock Is Down 7.93%
As of Tuesday, September 15, Armata Pharmaceuticals, Inc.’s ARMP share price has dipped by 7.93%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Armata Pharmaceuticals, Inc.’s (ARMP) Stock Is Down 16.22%
As of Tuesday, September 15, Armata Pharmaceuticals, Inc.’s ARMP share price has dipped by 16.22%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Armata Pharmaceuticals, Inc.’s (ARMP) Stock Is Up 11.71%
As of Monday, September 14, Armata Pharmaceuticals, Inc.’s ARMP share price has surged by 11.71%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | ARMP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $156.2 | $271.9 | 25% |
|
| Shares Out (Mil) | 62.0 | 54.2 | 52% |
|
| Institutional Ownership | 96.1% | 92.9% | 69% |
|
| Float (Mil) | 11.9 | 42.1 | 22% |
|
| Beta | 1.35 | 0.95 | 77% |
|
| Avg Daily Volume (000s) | 650 | 612 | 61% |
|
| Price Change (52-week) |
36.8% | 56.0% | 77% |
|
| Growth | ARMP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 43.7% | 13.1% | 94% |
|
| Net Income (5yr) | (50.9%) | (10.1%) | 7% |
|
| EPS (5yr) | (28.9%) | 15.7% | 8 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.8%) | (15.6%) | 46% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | ($0.380) | ($1.865) | ($1.445) | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | 0 | 1 | |
| # Rev Down | na | 0 | 0 | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | 39.7% | (61.1%) | (77.3%) | |
| Financials | ARMP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $6 | $37 | 6% |
|
| Net Income (TTM) (Mil) | ($192) | ($43) | 7% |
|
| EPS (TTM) | ($5.270) | ($1.500) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($25) | ($32) | 13% |
|
| Net Cash Flow (TTM) (Mil) | $18 | $2 | 61% |
|
| Long-Term Debt (Q1) (Mil) | $68 | $4 | 41% |
|
| Enterprise Value (Q1) (Mil) | $445 | $177 | 33% |
|
| Valuation | ARMP | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.67 | na |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ARMP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (217.4%) | 69.0% | 1% |
|
| Net Margin | na | (71.5%) | na |
|
| ROA | (225.1%) | (47.4%) | 2% |
|
| ROE | 127.8% | (54.6%) | 97% |
|
| Liabilities to Assets | 357.0% | 29.3% | 100% |
|
| F-Score | 2 | 3 | 7% |
|
Armata Pharmaceuticals, Inc. did not pass any screens on 9/22/2026.
